Your session is about to expire
← Back to Search
Nebulized sodium nitroprusside for Acute Lung Injury
Summary
Acute lung injury (ALI) is caused by a wide variety of conditions, but always characterized by hypoxia and non-cardiogenic pulmonary edema. Current treatment of ALI is supportive and treatment of the underlying cause. New therapies to treat severe ALI have not been shown to improve survival, and are limited by financial and logistical resources. The investigators propose to investigate the role of inhaled sodium nitroprusside (iSNP) in ALI. Sodium nitroprusside (SNP) is a vasodilator. When inhaled, SNP may travel to areas of the lung participating in gas exchange, and cause the blood vessels surrounding these areas to enlarge. This may result in an increase of blood vessels to these areas of the lung, and improve oxygenation. Currently, iSNP has not been studied in the adult population. Therefore, this study is intended to find the safety profile of varying doses of iSNP.
- Acute Lung Injury
- Hypoxia
- Acute Respiratory Distress Syndrome
- Sodium Nitroprusside
- Respiratory Failure
Timeline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2009 Phase 1 trial • 62 Patients • NCT00945256Trial Design
Find a Location
Who is running the clinical trial?
Share this study with friends
Copy Link
Messenger